These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 37778345)

  • 21. Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA.
    Kalinich M; Murphy W; Wongvibulsin S; Pahalyants V; Yu KH; Lu C; Wang F; Zubiri L; Naranbhai V; Gusev A; Kwatra SG; Reynolds KL; Semenov YR
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33789879
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association Between the Severity of Immune-related Adverse Events and the Prognosis in Patients With Non-small Cell Lung Cancer Receiving Treatment With Immune Checkpoint Inhibitors.
    Inomata M; Matsumoto M; Hayashi K; Seto Z; Hirai T; Tokui K; Taka C; Okazawa S; Kambara K; Imanishi S; Miwa T; Hayashi R; Matsui S; Tobe K
    Anticancer Res; 2023 Jul; 43(7):3241-3246. PubMed ID: 37351972
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk of Ophthalmic Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.
    Hou YL; Wang DY; Hu JX; Tian RY; Wang W; Su Q; Li H; Wang YL
    Ocul Immunol Inflamm; 2022 Aug; 30(6):1449-1459. PubMed ID: 33970759
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma.
    Abou Alaiwi S; Xie W; Nassar AH; Dudani S; Martini D; Bakouny Z; Steinharter JA; Nuzzo PV; Flippot R; Martinez-Chanza N; Wei X; McGregor BA; Kaymakcalan MD; Heng DYC; Bilen MA; Choueiri TK; Harshman LC
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32066646
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-world data analysis of immune checkpoint inhibitors in stage III-IV adenocarcinoma and squamous cell carcinoma.
    Sun M; Ji H; Xu N; Jiang P; Qu T; Li Y
    BMC Cancer; 2022 Jul; 22(1):762. PubMed ID: 35831785
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentre study from the European Academy of Dermatology and Venereology Task Force of Dermatology for Cancer Patients.
    Nikolaou VA; Apalla Z; Carrera C; Fattore D; Sollena P; Riganti J; Segura S; Freites-Martinez A; Lallas K; Romano MC; Oikonomou C; Starace M; Dimopoulos MA; Kyrgidis A; Lazaridou E; Giavedoni P; Annunziata MC; Peris K; Echeverría M; Lopez-Tujillo E; Syrigos K; Papageorgiou C; Podlipnik S; Fabbrocini G; Torre AC; Kemanetzi C; Villa-Crespo L; Lallas A; Stratigos AJ; Sibaud V
    Br J Dermatol; 2022 Dec; 187(6):962-969. PubMed ID: 35861701
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors.
    Tyan K; Baginska J; Brainard M; Giobbie-Hurder A; Severgnini M; Manos M; Haq R; Buchbinder EI; Ott PA; Hodi FS; Rahma OE
    Cancer Immunol Immunother; 2021 Aug; 70(8):2209-2221. PubMed ID: 33481042
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of concomitant medication on clinical outcomes in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors: A retrospective study.
    Miura K; Sano Y; Niho S; Kawasumi K; Mochizuki N; Yoh K; Matsumoto S; Zenke Y; Ikeda T; Nosaki K; Kirita K; Udagawa H; Goto K; Kawasaki T; Hanada K
    Thorac Cancer; 2021 Jul; 12(13):1983-1994. PubMed ID: 33990133
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lipidomics reveals immune-related adverse events in NSCLC patients receiving immune checkpoint inhibitor.
    Yu J; Xiong F; Xu Y; Xu H; Zhang X; Gao H; Li Y
    Int Immunopharmacol; 2024 Jan; 127():111412. PubMed ID: 38160567
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer.
    Shao J; Wang C; Ren P; Jiang Y; Tian P; Li W
    Biosci Rep; 2020 May; 40(5):. PubMed ID: 32315071
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer.
    Yan YD; Cui JJ; Fu J; Su YJ; Chen XY; Gu ZC; Lin HW
    Front Immunol; 2021; 12():760737. PubMed ID: 34925331
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of Corticosteroids for IrAEs on the Clinical Outcome of Immunotherapy in Patients With NSCLC.
    Shimomura K; Yamaguchi T; Oya Y; Uchida K; Murotani K
    Anticancer Res; 2022 Dec; 42(12):5961-5969. PubMed ID: 36456164
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety of current immune checkpoint inhibitors in non-small cell lung cancer.
    Abdayem P; Planchard D
    Expert Opin Drug Saf; 2021 Jun; 20(6):651-667. PubMed ID: 33393387
    [No Abstract]   [Full Text] [Related]  

  • 34. Impact of corticosteroid use on outcomes of non-small-cell lung cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis.
    Zhang H; Li X; Huang X; Li J; Ma H; Zeng R
    J Clin Pharm Ther; 2021 Aug; 46(4):927-935. PubMed ID: 34138497
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Corticosteroid administration for cancer-related indications is an unfavorable prognostic factor in solid cancer patients receiving immune checkpoint inhibitor treatment.
    Wang Y; Yang M; Tao M; Liu P; Kong C; Li H; Chen Y; Yin X; Yan X
    Int Immunopharmacol; 2021 Oct; 99():108031. PubMed ID: 34358857
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy.
    Cortellini A; Di Maio M; Nigro O; Leonetti A; Cortinovis DL; Aerts JG; Guaitoli G; Barbieri F; Giusti R; Ferrara MG; Bria E; D'Argento E; Grossi F; Rijavec E; Guida A; Berardi R; Torniai M; Sforza V; Genova C; Mazzoni F; Garassino MC; De Toma A; Signorelli D; Gelibter A; Siringo M; Marchetti P; Macerelli M; Rastelli F; Chiari R; Rocco D; Della Gravara L; Inno A; Michele T; Grassadonia A; Di Marino P; Mansueto G; Zoratto F; Filetti M; Santini D; Citarella F; Russano M; Cantini L; Tuzi A; Bordi P; Minuti G; Landi L; Ricciardi S; Migliorino MR; Passiglia F; Bironzo P; Metro G; Adamo V; Russo A; Spinelli GP; Banna GL; Friedlaender A; Addeo A; Cannita K; Ficorella C; Porzio G; Pinato DJ
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33827906
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune checkpoint inhibitor-associated interstitial lung diseases correlate with better prognosis in patients with advanced non-small-cell lung cancer.
    Sugano T; Seike M; Saito Y; Kashiwada T; Terasaki Y; Takano N; Hisakane K; Takahashi S; Tanaka T; Takeuchi S; Miyanaga A; Minegishi Y; Noro R; Kubota K; Gemma A
    Thorac Cancer; 2020 Apr; 11(4):1052-1060. PubMed ID: 32096610
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A text-mining approach to study the real-world effectiveness and potentially fatal immune-related adverse events of PD-1 and PD-L1 inhibitors in older patients with stage III/IV non-small cell lung cancer.
    Abedian Kalkhoran H; Zwaveling J; Storm BN; van Laar SA; Portielje JE; Codrington H; Luijten D; Brocken P; Smit EF; Visser LE
    BMC Cancer; 2023 Mar; 23(1):247. PubMed ID: 36918817
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emerging concerns of infectious diseases in lung cancer patients receiving immune checkpoint inhibitor therapy.
    Fujita K; Kim YH; Kanai O; Yoshida H; Mio T; Hirai T
    Respir Med; 2019 Jan; 146():66-70. PubMed ID: 30665520
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association Between Early Immune-related Adverse Events and Clinical Outcomes in Patients With Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.
    Hosoya K; Fujimoto D; Morimoto T; Kumagai T; Tamiya A; Taniguchi Y; Yokoyama T; Ishida T; Hirano K; Matsumoto H; Kominami R; Tomii K; Suzuki H; Hirashima T; Uchida J; Morita M; Kanazu M; Sawa N; Makio T; Hara S; Tamiya M
    Clin Lung Cancer; 2020 Jul; 21(4):e315-e328. PubMed ID: 32113737
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.